2 recruiting, 2 terminated, 1 completed, 1 withdrawn. 3 Phase 2, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
| Not applicable | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow Faeth Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Serabelisib, Sapanisertib, Fulvestrant - HR+ HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Faeth Therapeutics | 32 | 2026-04-22 | 2026-07-02 |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer Sapanisertib, Serabelisib, Paclitaxel - Endometrial Cancer | Phase 2 | Recruiting | Faeth Therapeutics | 40 | 2024-12-12 | 2025-12-24 |
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer sapanisertib - Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer | Phase 2 | Terminated | Faeth Therapeutics | 7 | 2022-07-21 | 2025-04-24 |
| Medical Food for the Dietary Management of Metastatic Colorectal Cancer NEAAR Medical Food - Metastatic Colorectal Cancer | Not applicable | Withdrawn | Faeth Therapeutics | 2022-04-27 | 2023-04-03 | |
| Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Serabelisib, Insulin Suppressing Diet, Nab paclitaxel - Advanced Solid Tumor, PIK3CA Mutation | Phase 1 | Terminated | Faeth Therapeutics | 34 | 2022-04-22 | 2026-04-30 |
| Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer NEAAR Medical Food - Metastatic Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma | Not applicable | Completed | Faeth Therapeutics | 39 | 2021-12-21 | 2025-07-18 |
Hereditary Sensory and Autonomic Neuropathies (2) · Breast Neoplasms (1) · Carcinoma, Endometrioid (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Genital Diseases (1) · Lung Neoplasms (1) · Recurrence (1)
sapanisertib (3) · serabelisib (3) · Fulvestrant (1) · Paclitaxel (1) · Taxes (1)
United States (5)
Andrea Cerceck, MD (1) · Andrew Hendifar, MD (1) · Paul Paik (1) · Vicky Makker (1)